Politan Capital Management said its candidates captured two board seats in Thursday’s shareholder vote, citing a preliminary analysis.
Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.
PET radiotracers facilitate the visualization of amyloid plaque density, enabling clinicians to assess people with cognitive impairment for Alzheimer’s and evaluate their response to treatment.
Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.
In April, a Securities and Exchange Commission filing revealed that Wojcicki planned to take the company private. 23andMe’s stock price had fallen below $1 per share at the time, down from its $10 ...
Koffey was elected to Masimo’s board in June 2023 along with Politan-backed candidate Michelle Brennan, a former Johnson & Johnson executive. The hedge fund argued that Masimo’s $1 billion acquisition ...
Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.
Senseonics and commercial partner Ascensia Diabetes Care received clearance from the Food and Drug Administration for the first implantable glucose sensor that can be worn for one year, doubling the ...
The patient can use his implant to turn on lights, make video calls, play music and shows, read books and buy products online without using his hands or voice.
The FDA posted a second Smiths recall on Wednesday related to a problem with certain ParaPac ventilator kits. A knob that sets the tidal volume, or the amount of air delivered with each breath, can ...
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.
Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.